What is the recommended peri‑operative anticoagulation bridging strategy for a patient with protein S deficiency who is on warfarin and is scheduled for surgery?

Perioperative Bridging for Protein S Deficiency

For patients with protein S deficiency on warfarin undergoing surgery, bridging anticoagulation with therapeutic-dose LMWH is recommended, following a standardized protocol that stops warfarin 5-6 days preoperatively, initiates LMWH 3 days before surgery, and carefully times postoperative resumption based on surgical bleeding risk.

Risk Stratification Framework

Protein S deficiency represents a high thromboembolic risk condition requiring bridging anticoagulation 1. This inherited thrombophilia places patients in the same risk category as antiphospholipid syndrome with recurrent thrombosis—conditions where the ACCP Guidelines explicitly recommend heparin bridging therapy 1.

The critical consideration is that protein S deficiency patients have demonstrated:

• Recurrent VTE risk even on therapeutic anticoagulation 2
• Particularly high risk when combined with other thrombophilic defects 2
• Potential for catastrophic thrombotic events during anticoagulation interruption

Preoperative Management Protocol

Warfarin Discontinuation

• Stop warfarin 5-6 days before surgery 1, 3
• For protein S deficiency patients (who may have higher baseline INR variability), consider stopping 6 days preoperatively
• Check INR on day before surgery; target INR ≤1.5 1
• If INR 1.5-1.8, administer low-dose oral vitamin K (1-2.5 mg) 1

LMWH Bridging Initiation

Start therapeutic-dose LMWH 36 hours after last warfarin dose (typically day -3) 1:

Dosing options 1:

• Enoxaparin: 1 mg/kg twice daily OR 1.5 mg/kg once daily subcutaneously
• Dalteparin: 100 IU/kg twice daily OR 200 IU/kg once daily subcutaneously
• Tinzaparin: 175 IU/kg once daily subcutaneously

Last preoperative LMWH dose:

• Administer 24 hours before surgery at half the total daily dose 1, 3
• This timing is critical—discontinuing LMWH closer to surgery increases bleeding risk due to residual anticoagulant effect 1

Postoperative Management

Warfarin Resumption

• Resume warfarin at usual maintenance dose on evening of surgery (day 0) or morning after (day 1) once adequate hemostasis achieved 1
• Do NOT use loading doses in high bleeding risk scenarios

LMWH Resumption: Bleeding Risk-Stratified Approach

For LOW-to-MODERATE bleeding risk procedures (e.g., cholecystectomy, hernia repair):

• Restart therapeutic-dose LMWH 24 hours postoperatively 1
• Continue LMWH until INR therapeutic (≥2.0) on two consecutive measurements 1

For HIGH bleeding risk procedures (e.g., neurosurgery, major cancer surgery, spinal procedures):

• Wait 48-72 hours after surgery before resuming therapeutic-dose LMWH 1, 3
• Consider prophylactic-dose LMWH (enoxaparin 40 mg daily or dalteparin 5000 IU daily) for first 24-72 hours 1
• Then transition to therapeutic-dose LMWH on day 2-3 postoperatively

Critical timing consideration: The evidence shows major bleed rates as high as 20% when therapeutic-dose LMWH is given postoperatively too close to surgery without regard for surgical bleeding risk 1.

Special Considerations for Protein S Deficiency

Why Bridging is Essential

Unlike atrial fibrillation (where recent evidence questions routine bridging), protein S deficiency is a hereditary thrombophilia with persistent hypercoagulable state. The ACCP Guidelines specifically recommend bridging for high thromboembolic risk conditions 1, and protein S deficiency falls squarely in this category.

Warfarin vs. DOACs

While DOACs are increasingly used for VTE, warfarin remains the preferred agent for protein S deficiency based on:

• Case reports showing DOAC failure in protein S deficiency with breakthrough thrombosis 4
• Evidence that reduced-dose DOACs have inadequate efficacy (8.1 VTE events per 100 patient-years) 2
• Warfarin with target INR 2.5-3.5 showing superior outcomes in protein S deficiency 4

Protein C/S Interaction Risk

Protein S deficiency patients are at risk for warfarin-induced skin necrosis when warfarin is initiated without adequate heparin overlap 5. This reinforces the importance of:

• Continuing therapeutic LMWH until INR is therapeutic for 2 consecutive days
• Never stopping LMWH prematurely postoperatively

Combined Thrombophilias

If protein S deficiency coexists with other thrombophilic conditions (Factor V Leiden, prothrombin mutation, protein C deficiency), the thrombotic risk is significantly amplified 2. These patients warrant:

• Extended postoperative LMWH bridging (consider 72 hours before resuming therapeutic dose)
• Target INR at higher end of therapeutic range (2.5-3.0 or even 2.5-3.5)
• Possible indefinite anticoagulation

Common Pitfalls to Avoid

1. Do NOT use prophylactic-dose LMWH for bridging—protein S deficiency requires therapeutic dosing 1

2. Do NOT resume therapeutic LMWH within 24 hours of high-bleeding-risk surgery—this dramatically increases major bleeding risk to 20% 1

3. Do NOT stop LMWH when warfarin is restarted—continue until INR therapeutic x2 measurements to prevent thrombosis during warfarin's delayed onset 6

4. Do NOT assume DOACs are equivalent to warfarin—protein S deficiency may require warfarin specifically 4, 2

5. Do NOT give last preoperative LMWH dose <24 hours before surgery—use half-dose at 24 hours 3

Laboratory Monitoring

• Preoperative: INR day before surgery (target ≤1.5) 1
• Postoperative: Check INR on day 4 postoperatively, then every 1-2 days until therapeutic 1
• Discontinue LMWH when INR >1.9-2.0 on two consecutive measurements 1
• Baseline labs 7-10 days preoperatively: hemoglobin, platelet count, creatinine, INR 1

This protocol balances the dual risks of thrombosis (inherent to protein S deficiency) and bleeding (inherent to surgery) through careful timing of anticoagulation interruption and resumption 1, 3.